Compare $CTMX vs $RGNX | Chartloom

Compare

$CTMX vs $RGNX

CytomX Therapeutics Inc · Regenxbio Inc

CTMX

CytomX Therapeutics Inc

RGNX

Regenxbio Inc

Compare $CTMX vs $RGNX

Comparing CytomX Therapeutics Inc and Regenxbio Inc

CTMXCytomX Therapeutics Inc

RGNXRegenxbio Inc

CTMXCytomX Therapeutics Inc

Market cap

$559M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

32.52x

Rev growth (TTM)

-87.0%

YTD performance

-39.5%

52W performance

-23.7%

FCF yield

-14.8%

RGNXRegenxbio Inc

Market cap

$511M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.95x

Rev growth (TTM)

12.0%

YTD performance

-40.5%

52W performance

-34.0%

FCF yield

-48.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CTMX

RGNX

Detailed metrics comparison

CTMX

CytomX Therapeutics Inc

RGNX

Regenxbio Inc

Market Cap

CTMX$559M

RGNX$511M

Enterprise Value

CTMX$542M

RGNX$656M

Price

CTMX$2.57

RGNX$8.07

P/E Ratio

CTMXN/A

RGNXN/A

P/S Ratio

CTMX30.57x

RGNX2.93x

EV/Sales

CTMX29.63x

RGNX3.76x

EV/EBITDA

CTMX22.17x

RGNX5.30x

P/B Ratio

CTMX1.85x

RGNX6.83x

P/FCF Ratio

CTMXN/A

RGNXN/A

EV/FCF

CTMX-6.55x

RGNX-2.63x

PEG Ratio

CTMXN/A

RGNXN/A

Forward P/E (NTM)

CTMXN/A

RGNXN/A

Forward P/S (NTM)

CTMX32.52x

RGNX5.95x

Revenue (TTM)

CTMX$18M

RGNX$174M

Revenue Growth (YoY)

CTMX-87.0%

RGNX12.0%

Forward Rev Growth

CTMX35.7%

RGNX25.9%

Gross Margin (TTM)

CTMX0.0%

RGNX86.4%

Operating Margin (TTM)

CTMX0.0%

RGNX0.0%

EBITDA Margin (TTM)

CTMX-471.6%

RGNX-85.3%

Net Margin (TTM)

CTMX-451.6%

RGNX-112.6%

FCF Margin (TTM)

CTMX-452.1%

RGNX-143.1%

Net Income (TTM)

CTMX$-83M

RGNX$-196M

FCF (TTM)

CTMX$-83M

RGNX$-250M

EPS (TTM)

CTMX-$0.38

RGNX-$3.71

ROE (TTM)

CTMX-3846.0%

RGNX-22007.0%

ROA (TTM)

CTMX-3033.0%

RGNX-4604.0%

ROIC (TTM)

CTMX-3846.0%

RGNX-7179.0%

Cash

CTMX$17M

RGNX$36M

Debt

CTMX$0

RGNX$182M

Net Cash/Debt

CTMX$17M

RGNX$-145M

Current Ratio (TTM)

CTMX9.36x

RGNX2.86x

Quick Ratio (TTM)

CTMX9.25x

RGNX2.71x

Debt/Equity (TTM)

CTMX0.00x

RGNX2.53x

Debt/Assets (TTM)

CTMX0.0%

RGNX0.0%

Interest Coverage (TTM)

CTMXN/A

RGNXN/A

Net Debt/EBITDA (TTM)

CTMX0.00x

RGNX0.00x

Beta

CTMX2.26

RGNX1.21

52W Performance

CTMX-23.7%

RGNX-34.0%

YTD Performance

CTMX-39.5%

RGNX-40.5%

% from 52W High

CTMX-68.7%

RGNX-50.2%

% from 52W Low

CTMX5.8%

RGNX47.9%

Asset Turnover (TTM)

CTMX0.07x

RGNX0.41x

FCF Yield (TTM)

CTMX-14.8%

RGNX-48.9%

Earnings Yield (TTM)

CTMX-14.8%

RGNX-38.5%

Dividend Yield (TTM)

CTMXN/A

RGNXN/A

Rule of 40

CTMX-539.1

RGNX-131.1

EV/GP/RG

CTMXN/A

RGNX0.15

Ticker research

View CTMX research View RGNX research

Metric	CTMX CytomX Therapeutics Inc	RGNX Regenxbio Inc
Market & Valuation
Market Cap	$559M	$511M
Enterprise Value	$542M	$656M
Price	$2.57	$8.07
P/E Ratio	N/A	N/A
P/S Ratio	30.57x	2.93x
EV/Sales	29.63x	3.76x
EV/EBITDA	22.17x	5.30x
P/B Ratio	1.85x	6.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.55x	-2.63x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	32.52x	5.95x
Revenue & Growth
Revenue (TTM)	$18M	$174M
Revenue Growth (YoY)	-87.0%	12.0%
Forward Rev Growth	35.7%	25.9%
Profitability
Gross Margin (TTM)	0.0%	86.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-471.6%	-85.3%
Net Margin (TTM)	-451.6%	-112.6%
FCF Margin (TTM)	-452.1%	-143.1%
Net Income (TTM)	$-83M	$-196M
FCF (TTM)	$-83M	$-250M
EPS (TTM)	-$0.38	-$3.71
ROE (TTM)	-3846.0%	-22007.0%
ROA (TTM)	-3033.0%	-4604.0%
ROIC (TTM)	-3846.0%	-7179.0%
Financial Health
Cash	$17M	$36M
Debt	$0	$182M
Net Cash/Debt	$17M	$-145M
Current Ratio (TTM)	9.36x	2.86x
Quick Ratio (TTM)	9.25x	2.71x
Debt/Equity (TTM)	0.00x	2.53x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.26	1.21
52W Performance	-23.7%	-34.0%
YTD Performance	-39.5%	-40.5%
% from 52W High	-68.7%	-50.2%
% from 52W Low	5.8%	47.9%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.41x
FCF Yield (TTM)	-14.8%	-48.9%
Earnings Yield (TTM)	-14.8%	-38.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-539.1	-131.1
EV/GP/RG	N/A	0.15
Ticker research	View CTMX research	View RGNX research

Valuation

P/S Ratio

RGNX

2.93x

CTMX

30.57x

EV/FCF

CTMX

-6.55x

RGNX

-2.63x

Growth & revenue

Revenue Growth TTM

RGNX

12.0%

CTMX

-87.0%

Forward Revenue Growth

CTMX

35.7%

RGNX

25.9%

Profitability & performance

Gross Margin

RGNX

86.4%

CTMX

0.0%

ROE

CTMX

-3846.0%

RGNX

-22007.0%

FCF Yield %

CTMX

-14.8%

RGNX

-48.9%

52-Week Performance

CTMX

-23.7%

RGNX

-34.0%

Detailed metrics comparison

CTMX

CytomX Therapeutics Inc

RGNX

Regenxbio Inc

Market Cap

CTMX$559M

RGNX$511M

Enterprise Value

CTMX$542M

RGNX$656M

Price

CTMX$2.57

RGNX$8.07

P/E Ratio

CTMXN/A

RGNXN/A

P/S Ratio

CTMX30.57x

RGNX2.93x

EV/Sales

CTMX29.63x

RGNX3.76x

EV/EBITDA

CTMX22.17x

RGNX5.30x

P/B Ratio

CTMX1.85x

RGNX6.83x

P/FCF Ratio

CTMXN/A

RGNXN/A

EV/FCF

CTMX-6.55x

RGNX-2.63x

PEG Ratio

CTMXN/A

RGNXN/A

Forward P/E (NTM)

CTMXN/A

RGNXN/A

Forward P/S (NTM)

CTMX32.52x

RGNX5.95x

Revenue (TTM)

CTMX$18M

RGNX$174M

Revenue Growth (YoY)

CTMX-87.0%

RGNX12.0%

Forward Rev Growth

CTMX35.7%

RGNX25.9%

Gross Margin (TTM)

CTMX0.0%

RGNX86.4%

Operating Margin (TTM)

CTMX0.0%

RGNX0.0%

EBITDA Margin (TTM)

CTMX-471.6%

RGNX-85.3%

Net Margin (TTM)

CTMX-451.6%

RGNX-112.6%

FCF Margin (TTM)

CTMX-452.1%

RGNX-143.1%

Net Income (TTM)

CTMX$-83M

RGNX$-196M

FCF (TTM)

CTMX$-83M

RGNX$-250M

EPS (TTM)

CTMX-$0.38

RGNX-$3.71

ROE (TTM)

CTMX-3846.0%

RGNX-22007.0%

ROA (TTM)

CTMX-3033.0%

RGNX-4604.0%

ROIC (TTM)

CTMX-3846.0%

RGNX-7179.0%

Cash

CTMX$17M

RGNX$36M

Debt

CTMX$0

RGNX$182M

Net Cash/Debt

CTMX$17M

RGNX$-145M

Current Ratio (TTM)

CTMX9.36x

RGNX2.86x

Quick Ratio (TTM)

CTMX9.25x

RGNX2.71x

Debt/Equity (TTM)

CTMX0.00x

RGNX2.53x

Debt/Assets (TTM)

CTMX0.0%

RGNX0.0%

Interest Coverage (TTM)

CTMXN/A

RGNXN/A

Net Debt/EBITDA (TTM)

CTMX0.00x

RGNX0.00x

Beta

CTMX2.26

RGNX1.21

52W Performance

CTMX-23.7%

RGNX-34.0%

YTD Performance

CTMX-39.5%

RGNX-40.5%

% from 52W High

CTMX-68.7%

RGNX-50.2%

% from 52W Low

CTMX5.8%

RGNX47.9%

Asset Turnover (TTM)

CTMX0.07x

RGNX0.41x

FCF Yield (TTM)

CTMX-14.8%

RGNX-48.9%

Earnings Yield (TTM)

CTMX-14.8%

RGNX-38.5%

Dividend Yield (TTM)

CTMXN/A

RGNXN/A

Rule of 40

CTMX-539.1

RGNX-131.1

EV/GP/RG

CTMXN/A

RGNX0.15

Ticker research

View CTMX research View RGNX research

Metric	CTMX CytomX Therapeutics Inc	RGNX Regenxbio Inc
Market & Valuation
Market Cap	$559M	$511M
Enterprise Value	$542M	$656M
Price	$2.57	$8.07
P/E Ratio	N/A	N/A
P/S Ratio	30.57x	2.93x
EV/Sales	29.63x	3.76x
EV/EBITDA	22.17x	5.30x
P/B Ratio	1.85x	6.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.55x	-2.63x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	32.52x	5.95x
Revenue & Growth
Revenue (TTM)	$18M	$174M
Revenue Growth (YoY)	-87.0%	12.0%
Forward Rev Growth	35.7%	25.9%
Profitability
Gross Margin (TTM)	0.0%	86.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-471.6%	-85.3%
Net Margin (TTM)	-451.6%	-112.6%
FCF Margin (TTM)	-452.1%	-143.1%
Net Income (TTM)	$-83M	$-196M
FCF (TTM)	$-83M	$-250M
EPS (TTM)	-$0.38	-$3.71
ROE (TTM)	-3846.0%	-22007.0%
ROA (TTM)	-3033.0%	-4604.0%
ROIC (TTM)	-3846.0%	-7179.0%
Financial Health
Cash	$17M	$36M
Debt	$0	$182M
Net Cash/Debt	$17M	$-145M
Current Ratio (TTM)	9.36x	2.86x
Quick Ratio (TTM)	9.25x	2.71x
Debt/Equity (TTM)	0.00x	2.53x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.26	1.21
52W Performance	-23.7%	-34.0%
YTD Performance	-39.5%	-40.5%
% from 52W High	-68.7%	-50.2%
% from 52W Low	5.8%	47.9%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.41x
FCF Yield (TTM)	-14.8%	-48.9%
Earnings Yield (TTM)	-14.8%	-38.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-539.1	-131.1
EV/GP/RG	N/A	0.15
Ticker research	View CTMX research	View RGNX research